NCT04817826View on ClinicalTrials.gov

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2026

Conditions
Gastric CancerMicrosatellite Instability
Interventions
DRUG

Durvalumab

durvalumab 1500 mg Q4W for 3 cycles (day 1, 29 and 57).

DRUG

Tremelimumab

tremelimumab 300 mg single administration (day 1)

Trial Locations (1)

20133

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan

All Listed Sponsors
lead

Gruppo Oncologico del Nord-Ovest

OTHER